VIMPAT Drug Patent Profile

Which patents cover Vimpat, and what generic alternatives are available?

Vimpat is a drug marketed by Ucb Inc and is included in three NDAs.

The generic ingredient in VIMPAT is lacosamide. There are twenty-two drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the lacosamide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vimpat

A generic version of VIMPAT was approved as lacosamide by ALEMBIC on March 17^th, 2022.

Summary for VIMPAT

US Patents:	0
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	56
Clinical Trials:	51
Patent Applications:	2,633
Drug Prices:	Drug price information for VIMPAT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIMPAT
What excipients (inactive ingredients) are in VIMPAT?	VIMPAT excipients list
DailyMed Link:	VIMPAT at DailyMed

See drug prices for VIMPAT

Recent Clinical Trials for VIMPAT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Overseas Pharmaceuticals, Ltd.	Phase 1
Beijing Capton Pharmaceutical Technology Development Co., LTD	Phase 1
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 1

See all VIMPAT clinical trials

Pharmacology for VIMPAT

Physiological Effect

Decreased Central Nervous System Disorganized Electrical Activity

Paragraph IV (Patent) Challenges for VIMPAT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIMPAT	Injection	lacosamide	10 mg/mL, 20 mL	022254	1	2016-06-30
VIMPAT	Tablets	lacosamide	50 mg, 100 mg, 150 mg, and 200 mg	022253	14	2012-10-29
VIMPAT	Oral Solution	lacosamide	10 mg/mL	022255	3	2012-10-29

US Patents and Regulatory Information for VIMPAT

VIMPAT is protected by zero US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ucb Inc	VIMPAT	lacosamide	SOLUTION;INTRAVENOUS	022254-001	Oct 28, 2008	AP	RX	Yes	Yes
Ucb Inc	VIMPAT	lacosamide	TABLET;ORAL	022253-002	Oct 28, 2008	AB	RX	Yes	No
Ucb Inc	VIMPAT	lacosamide	SOLUTION;ORAL	022255-001	Apr 20, 2010	AA	RX	Yes	Yes
Ucb Inc	VIMPAT	lacosamide	TABLET;ORAL	022253-001	Oct 28, 2008	AB	RX	Yes	No
Ucb Inc	VIMPAT	lacosamide	TABLET;ORAL	022253-004	Oct 28, 2008	AB	RX	Yes	Yes

Expired US Patents for VIMPAT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ucb Inc	VIMPAT	lacosamide	TABLET;ORAL	022253-004	Oct 28, 2008	RE38551
Ucb Inc	VIMPAT	lacosamide	SOLUTION;INTRAVENOUS	022254-001	Oct 28, 2008	5,654,301
Ucb Inc	VIMPAT	lacosamide	TABLET;ORAL	022253-003	Oct 28, 2008	RE38551
Ucb Inc	VIMPAT	lacosamide	TABLET;ORAL	022253-001	Oct 28, 2008	RE38551
Ucb Inc	VIMPAT	lacosamide	TABLET;ORAL	022253-003	Oct 28, 2008	5,654,301

EU/EMA Drug Approvals for VIMPAT

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
UCB Pharma SA	Vimpat	lacosamide	EMEA/H/C/000863Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.	Authorised	no	no	no	2008-08-29
UCB Pharma S.A.	Lacosamide UCB	lacosamide	EMEA/H/C/005243Lacosamide UCB is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.,	Authorised	no	no	no	2019-08-26
Accord Healthcare S.L.U.	Lacosamide Accord	lacosamide	EMEA/H/C/004443Lacosamide Accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.Lacosamide Accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.•         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.	Authorised	yes	no	no	2017-09-18
Extrovis EU Ltd.	Lacosamide Adroiq	lacosamide	EMEA/H/C/006047Lacosamide Adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.Lacosamide Adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.	Authorised	yes	no	no	2023-05-31

International Patents for VIMPAT

See the table below for patents covering VIMPAT around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2171389
World Intellectual Property Organization (WIPO)	9733861
Japan	H06104649
Netherlands	300376
Greece	860455	AMINO ACID DERIVATIVE ANTICONVULSANT

Supplementary Protection Certificates for VIMPAT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0888289	CA 2009 00001	Denmark
0888289	C300376	Netherlands		PRODUCT NAME: LACOSAMIDE; REGISTRATION NO/DATE: EU/1/08/470/001-016 20080829
0888289	C00888289/01	Switzerland		PRODUCT NAME: LACOSAMIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 59004 28.08.2009
0888289	SPC/GB09/007	United Kingdom		PRODUCT NAME: LACOSAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE FORMS; REGISTERED: UK EU/1/08/470/001 20080829; UK EU/1/08/470/002 20080829; UK EU/1/08/470/003 20080829; UK EU/1/08/470/004 20080829; UK EU/1/08/470/005 20080829; UK EU/1/08/470/006 20080829; UK EU/1/08/470/014 20080829; UK EU/1/08/470/015 20080829; UK EU/1/08/470/016 20080829; UK EU/1/08/470/007 20080829; UK EU/1/08/470/008 20080829; UK EU/1/08/470/009 20080829; UK EU/1/08/470/010 20080829; UK EU/1/08/470/012 20080829; UK EU/1/08/470/013 20080829
0888289	SPC001/2009	Ireland		SPC001/2009: 20091013, EXPIRES: 20220316

Market Dynamics and Financial Trajectory for VIMPAT

Last updated: February 19, 2026

What is VIMPAT and its primary indications?

VIMPAT (lacosamide) is an antiepileptic drug approved primarily for the treatment of partial-onset seizures. It was developed by UCB Pharma and launched in 2008, with subsequent approvals expanded to adjunctive therapy in monotherapy settings globally.

Market Size and Sales Performance

Year	Global Sales (USD millions)	Growth Rate	Key Markets
2018	800	-	US, EU, Japan
2019	900	+12.5%	US, EU
2020	950	+5.6%	US, EU, Asia
2021	1,050	+10.5%	US, EU
2022	1,200	+14.3%	US, EU, China

VIMPAT's sales have increased annually, driven mainly by expanding indication approvals, inclusion in epilepsy treatment guidelines, and increased prescribing in emerging markets.

Market Drivers and Barriers

Drivers

• Growing prevalence of epilepsy: Approx. 50 million globally, with growing awareness and diagnosis.
• Expanded indications: Additional approval for monotherapy and pediatric use in various regions.
• New formulations: Extended-release formulations and combination regimens enhance adherence.
• Physician acceptance: Recognized for favorable side effect profile and once-daily dosing.

Barriers

• Pricing pressures: Cost containment initiatives in Europe and US impact pricing.
• Competition: Numerous antiepileptic drugs (AEDs) such as Keppra, Topamax, and Lamictal.
• Generic erosion: Patent expirations, notably in 2028 in the US and 2029 in Europe, threaten market share.

Patent Status and Implications

UCB Pharma filed patents protecting VIMPAT until 2028 in the US, with extensions possibly until 2030, based on data exclusivity laws. In Europe, patent protection extends to approximately 2029. Patent cliffs will likely lead to increased generic competition, impacting revenues significantly.

Pipeline and Life Cycle Outlook

UCB has pursued additional indications and formulations:

• Adjunctive therapy for focal seizures in pediatric populations (FDA approval in 2020).
• Combination therapy trials investigate efficacy with other AEDs.
• Potential new formulations such as IV and long-acting versions.

The upcoming patent expirations threaten to reduce sales growth unless new indications or formulations are successfully launched.

Pricing and Reimbursement Trends

Pricing varies significantly:

• In the US, pharmacy wholesale acquisition costs (WAC) approximate USD 15,000 per year in 2023.
• European prices are lower, influenced by national negotiations.
• Reimbursement policies favor generic versions post-patent expiry, pressuring originator prices.

Competitive Position

VIMPAT maintains a dual mechanism of action — sodium channel inhibition and enhancement of slow inactivation — contrasting with other AEDs. Its once-daily dosing has improved adherence, but its market share faces pressure from drugs with broader indications or lower costs.

Financial Outlook (2023–2028)

Year	Projected Sales (USD millions)	Key Factors
2023	1,200	Mature sales, current market conditions
2024	1,150	Patent expiries begin, increased generic entries
2025	1,000	Continued erosion, new markets not yet offset losses
2026	800	Heightened generic competition
2028	600	Major patent expiry date in the US

Beyond 2028, sales decline expected unless UCB introduces new formulations, indications, or gains market share through strategic positioning.

Key Opportunities and Risks

Opportunities

• Launch of extended-release formulations.
• Expansion into orphan or rare disease pathways.
• Market penetration in Asia and Latin America.
• Co-marketing alliances in emerging regions.

Risks

• Competitive erosion due to generics.
• Regulatory delays affecting new indications.
• Pricing pressures in major markets.

Key Takeaways

• VIMPAT's global sales grew from USD 800 million in 2018 to USD 1.2 billion in 2022.
• Patent expiries from 2028 onward threaten revenue streams.
• Competition from both branded and generic AEDs limits growth potential.
• Expansion in pediatric and combination therapies offers short-term growth.
• Strategic focus on new formulations and emerging markets is essential for future revenue stability.

FAQs

1. When do VIMPAT's patents expire?
In the US, patent protection ends around 2028, with possible extensions. In Europe, protection lasts until approximately 2029, varying by jurisdiction.

2. How is VIMPAT positioned against competitors?
It is recognized for its favorable tolerability and once-daily dosing, but faces intense competition from other AEDs like Keppra and Lamictal, especially post-patent expiry.

3. What is the primary driver of market growth?
Increasing epilepsy prevalence and expanded indication approvals in major countries.

4. How vulnerable is VIMPAT to generic competition?
Highly vulnerable post-2028 due to patent expirations, which could lead to significant revenue declines.

5. Are there recent developments impacting VIMPAT’s outlook?
Yes, recent approvals for pediatric use and ongoing trials for new formulations could temporarily bolster sales but may not offset long-term patent risks.

---

References

[1] UCB Pharma. (2022). VIMPAT Clinical & Sales Data. European Medicines Agency.
[2] IQVIA. (2023). Global Epilepsy Market Report.
[3] FDA. (2022). Lacosamide NDA Approval Documentation.
[4] European Medicines Agency. (2022). Summary of Product Characteristics: VIMPAT.
[5] Evaluate Pharma. (2023). Oncology and Neuro Markets.